The transformation of nascent disc shaped high density lipoproteins into mature spherical high density lipoproteins: conformational analysis of apolipoprotein A-I in model intermediate particles. 1994

C Talussot, and G Ponsin
Laboratoire de Métabolisme des Lipides, INSERM U 63, Hôpital de l'Antiquaille, Lyon, France.

The conformation of apolipoprotein A-I (apo A-I) was studied in reassembled lipoprotein particles containing various proportions of apo A-I, phospholipids and cholesteryl esters or triglycerides, using both theoretical and experimental approaches. The proportions of the components were chosen to permit the formation of swollen discs mimicking the intermediate particles that must result from the lecithin:cholesterol acyl transferase (LCAT)-mediated transformation of nascent discoidal high-density lipoprotein (HDL) into mature spherical HDL. Three groups of particles were defined by the number of helices per apo A-I molecule that could fit the edge of the swollen discs. Groups I, II and III had six, seven and eight helices per apo A-I, respectively. The conformation of apo A-I was studied by quenching of tryptophan fluorescence in the presence of KI. In all groups the tryptophan (Trp) residues belonging to the helices located on the edge of the particles were very sparingly hydrated. In contrast, the degree of hydration of Trp residues in external position was different in each group. The structural organization of phospholipids was assessed by measurements of the fluorescence anisotropy of 1-(4-trimethylammonium phenyl)-6-phenyl-1,3,5-hexatriene (TMA-DPH) probe. In group I, which contained the less swollen particles, a segment of apo A-I of about 46 amino acids contributed to the area of the faces of the particles, resulting in a highly condensed and ordered phospholipid matrix. In groups II and III, the external segment of apo A-I did not interact with phospholipids.

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D016632 Apolipoprotein A-I The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE. Apo A-I,Apo A-1,Apo A-I Isoproteins,Apo A1,Apo AI,ApoA-1,ApoA-I,Apolipoprotein A-1,Apolipoprotein A-I Isoprotein-2,Apolipoprotein A-I Isoprotein-4,Apolipoprotein A-I Isoproteins,Apolipoprotein A1,Apolipoprotein AI,Apolipoprotein AI Propeptide,Pro-Apo A-I,Pro-Apolipoprotein A-I,Proapolipoprotein AI,Apo A I Isoproteins,Apolipoprotein A 1,Apolipoprotein A I,Apolipoprotein A I Isoprotein 2,Apolipoprotein A I Isoprotein 4,Apolipoprotein A I Isoproteins,Pro Apo A I,Pro Apolipoprotein A I

Related Publications

C Talussot, and G Ponsin
May 2018, Proceedings of the National Academy of Sciences of the United States of America,
C Talussot, and G Ponsin
January 2011, The Journal of biological chemistry,
C Talussot, and G Ponsin
August 2008, Proceedings of the National Academy of Sciences of the United States of America,
C Talussot, and G Ponsin
August 2007, The Journal of biological chemistry,
C Talussot, and G Ponsin
January 2000, Journal of lipid research,
C Talussot, and G Ponsin
March 1990, Clinical chemistry,
Copied contents to your clipboard!